WO2013166264A3 - Methods for altering virus replication - Google Patents

Methods for altering virus replication Download PDF

Info

Publication number
WO2013166264A3
WO2013166264A3 PCT/US2013/039234 US2013039234W WO2013166264A3 WO 2013166264 A3 WO2013166264 A3 WO 2013166264A3 US 2013039234 W US2013039234 W US 2013039234W WO 2013166264 A3 WO2013166264 A3 WO 2013166264A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
viral replication
virus
altering
virus replication
Prior art date
Application number
PCT/US2013/039234
Other languages
French (fr)
Other versions
WO2013166264A2 (en
Inventor
Ralph A. Tripp
Stephen M. Tompkins
Abhijeet BAKRE
Original Assignee
University Of Georgia Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Georgia Research Foundation, Inc. filed Critical University Of Georgia Research Foundation, Inc.
Publication of WO2013166264A2 publication Critical patent/WO2013166264A2/en
Publication of WO2013166264A3 publication Critical patent/WO2013166264A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

Provided herein are methods for altering viral replication in a cell. The virus may be a member of the family Orthomyxoviridae, such as an influenza virus, or a member of the family Paramyxoviridae, such as human respiratory syncytial virus. Altering viral replication is accomplished through the use of polynucleotides. In one embodiment, a polynucleotide decreases expression of a polypeptide, such as a protease or a kinase. In one embodiment, a polynucleotide is an miRNA or an miRNA inhibitor. In some embodiments viral replication is decreased, and in other embodiments viral replication is increased. Also included are methods for treating a subject, and genetically modified cells having the characteristic of altered virus replication compared to a control cell.
PCT/US2013/039234 2012-05-02 2013-05-02 Methods for altering virus replication WO2013166264A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261641664P 2012-05-02 2012-05-02
US61/641,664 2012-05-02

Publications (2)

Publication Number Publication Date
WO2013166264A2 WO2013166264A2 (en) 2013-11-07
WO2013166264A3 true WO2013166264A3 (en) 2014-01-16

Family

ID=49515035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/039234 WO2013166264A2 (en) 2012-05-02 2013-05-02 Methods for altering virus replication

Country Status (1)

Country Link
WO (1) WO2013166264A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017007784A1 (en) * 2015-07-06 2017-01-12 University Of Georgia Research Foundation Methods and compositions related to increased influenza virus production
CN108884461A (en) 2015-11-24 2018-11-23 联邦科学技术研究组织 Virus is generated in birds, beasts and eggs
US11174466B2 (en) 2015-11-24 2021-11-16 Commonwealth Scientific And Industrial Research Organisation Production of viruses in cell culture
MA45496A (en) 2016-06-17 2019-04-24 Hoffmann La Roche NUCLEIC ACID MOLECULES FOR PADD5 OR PAD7 MRNA REDUCTION FOR TREATMENT OF HEPATITIS B INFECTION
KR102619197B1 (en) 2017-01-23 2024-01-03 리제너론 파마슈티칼스 인코포레이티드 HSD17B13 variant and its uses
JP2020516283A (en) 2017-04-11 2020-06-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Assay for screening the activity of modulators of hydroxysteroid (17-beta) dehydrogenase (HSD17B) family members
WO2019075181A1 (en) 2017-10-11 2019-04-18 Regeneron Pharmaceuticals, Inc. Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation
SG11202003461TA (en) 2017-10-16 2020-05-28 Hoffmann La Roche NUCLEIC ACID MOLECULE FOR REDUCTION OF PAPD5 AND PAPD7 mRNA FOR TREATING HEPATITIS B INFECTION
CA3103054A1 (en) 2018-07-03 2020-01-09 F. Hoffmann-La Roche Ag Oligonucleotides for modulating tau expression
CA3123890A1 (en) * 2019-01-04 2020-07-09 Cargill Incorporated Engineered nucleases to generate mutations in plants
CN110261611B (en) * 2019-06-14 2021-06-22 上海四核生物科技有限公司 Application of ZNF709 protein as gastric cancer serum biomarker and kit thereof
WO2022119560A1 (en) * 2020-12-01 2022-06-09 National Health Research Institutes Cell strain having increased virus production ability and production method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057461A2 (en) * 2001-01-18 2002-07-25 Bayer Aktiengesellschaft Regulation of human adam-ts-like zinc metalloprotease
US20090170720A1 (en) * 2004-10-15 2009-07-02 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2011017535A2 (en) * 2009-08-05 2011-02-10 University Of South Florida Method of rapidly visualizing essential neural pathways
WO2012045067A2 (en) * 2010-10-01 2012-04-05 Zirus, Inc. Mammalian genes involved in infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002057461A2 (en) * 2001-01-18 2002-07-25 Bayer Aktiengesellschaft Regulation of human adam-ts-like zinc metalloprotease
US20090170720A1 (en) * 2004-10-15 2009-07-02 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
WO2011017535A2 (en) * 2009-08-05 2011-02-10 University Of South Florida Method of rapidly visualizing essential neural pathways
WO2012045067A2 (en) * 2010-10-01 2012-04-05 Zirus, Inc. Mammalian genes involved in infection

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MELIOPOULOS.: "UNDERSTANDING HOST PROTEASE GENE INVOLVEMENT DURING INFLUENZA VIRUS REPLICATION AS A POTENTIAL DISEASE INTERVENTION STRATEGY", DOCTORAL DISSERTATION, December 2011 (2011-12-01), pages 1 - 222 *

Also Published As

Publication number Publication date
WO2013166264A2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
WO2013166264A3 (en) Methods for altering virus replication
WO2014123967A3 (en) Cell lines for virus production and methods of use
WO2017064566A3 (en) Inducible modification of a cell genome
IL244597B (en) Inhibitors of influenza viruses replication, compositions comprising the same and uses thereof
IL236231A0 (en) Preparation, uses and solid forms of obeticholic acid
WO2016037154A8 (en) Recombinant hiv-1 envelope proteins and their use
JP2012140442A5 (en)
HK1211289A1 (en) Dihydroxypyrimidine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2014197568A3 (en) Rna-guideded transcriptional regulation
HK1205128A1 (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease 7--
WO2014177546A3 (en) Glucoamylase variants and polynucleotides encoding same
EP3070163A4 (en) Method for preparing induced pluripotent stem cell, composition used in method, and uses thereof
CO6811861A2 (en) Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
WO2013105827A3 (en) Recombinant microorganism having improved putrescine producing ability and method for producing putrescine by using same
WO2013188848A3 (en) Antiviral compounds and methods of use
EP2964754A4 (en) Individualized high purity hepatocellular carcinoma stem cells, methods and use of the same
JP2013140343A5 (en)
WO2015017316A3 (en) Methods and compositions for modifying mucous membranes
WO2012103496A3 (en) Expression of soluble viral fusion glycoproteins in mammalian cells
WO2013124807A3 (en) Oligonucleotides for modulating gene expression and uses thereof
HK1219500A1 (en) Genetically stable oncolytic rna virus, method of manufacturing and use thereof rna
EP2964789A4 (en) Isothermal amplification of nuleic acid, and library preparation and clone generation in sequencing
EP2822654A4 (en) Orally active, cell-penetrating homing peptide and methods of using same
WO2012122465A3 (en) Yeast with reduced 2,3-butanediol accumulation
HK1217457A1 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13785192

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13785192

Country of ref document: EP

Kind code of ref document: A2